Glomerulonephritis Clinical Trials

A listing of Glomerulonephritis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

  • 0 views
  • 04 Oct, 2022
  • 33 locations
Different Immunosuppressive Treatment in iMN

The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)

  • 2 views
  • 30 Apr, 2022
  • 1 location
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NOBLE)

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

mpgn
chronic kidney disease
  • 3 views
  • 05 May, 2022
  • 21 locations
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

nephropathy
proteinuria
immunoglobulin a
immunoglobulins
glomerular filtration rate
  • 486 views
  • 05 Mar, 2022
  • 30 locations
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of LNP023 at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

hbeag
nephropathy
proteinuria
fibrosis
adrenaline
  • 45 views
  • 24 Oct, 2022
  • 170 locations
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

renal function
nephropathy
  • 47 views
  • 04 Oct, 2022
  • 119 locations
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

nephropathy
proteinuria
enzyme inhibitor
monoclonal antibodies
  • 0 views
  • 04 Oct, 2022
  • 21 locations
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

nephropathy
fibrosis
kidney biopsy
monoclonal antibodies
  • 0 views
  • 07 Oct, 2022
  • 12 locations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis (POSTERITY)

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics of obinutuzumab in adolescent participants aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).

prednisone
proteinuria
mycophenolate
diphenhydramine
mammogram
  • 0 views
  • 24 Oct, 2022
  • 25 locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY) (REGENCY)

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

prednisone
kidney biopsy
mycophenolate
diphenhydramine
mammogram
  • 21 views
  • 24 Oct, 2022
  • 99 locations